While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations.
This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology.
SYSTEMIC AND ENDOLUMINAL THERAPY. Principles of Antithrombotic Therapy. Principles of Antiplatelet Therapy. Glycoprotein Iib/Iiia Inhibitors. ADP Receptor Inhibitors. Phosphodiesterase Inhibitors. Heparin, Low Molecular Weight Heparin, Heparinoids. Direct Thrombin Inhibitors. Parenteral Direct Antithrombin. Oral Antithrombin Drugs. Antixa Drugs. Combined Anticoagulant and Antiplatelet Therapy. Thrombolytics-Fibrinolytic Therapy. Resistance to Anti-Platelet Drugs. Fibrin Glue and Related Sealants. Lipid-Lowering Agents. Antihypertensive Agents. Homocysteine Regulators. Role of Systemic Anti-Restenotic Drugs and Results of Current Clinical Trials. Oral Anti-Neoplastic Agents For Prevention of Restenosis. Antioxidants. Iron Chelation: Deferoxamine and Beyond. LOCAL THERAPY. Principles of Local Catheter Delivery. Stent-mediated Local Drug Delivery. Brachytherapy. Platforms of Local Delivery. Polymers. Biopolymers. Classification of Anti-restenotic Drugs. Anti-proliferative Compounds (Taxol, Actinomycin, Vasenoids) and Mechanisms of Action. Anti-inflammatory Drugs (Sirolimus, Steroids) and Mechanisms of Action. Anti-migratory Drugs and Mechanisms of Action. Anti-angiogenesis Drugs and mechanism of action. Vasculoprotective Approach for Restenosis. Nitric Oxide Donors. Estradiols. VEGF. Gene Therapy. Antisense Approach. Principles of PDT. Therapeutic Angiogenesis.Characteristics of Different Delivery Devices. Periadventitial Delivery of Drugs. Angiogenesis and Myogenesis. Growth Factor Therapy. Stem Cell Transplantation. Results of Recent Clinical Trials. ADJUNCTIVE PHARMACOTHERAPY. The Heart Failure Patient. The Acute Coronary Syndrome Patient 48. The Diabetic Patient. The Stroke Patient. Atrial Fibrillation . Pregnancy and PCI. Contrast-induced Nephropathy after PCI . Erectile Dysfunction. Carotid Stenting. Peripheral Vascular Disease. Drug Interaction in Patients Undergoing Cardiovascular and Vascular Interventions. Newer Pharmacologic Approaches Targeting Receptors an